These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

80 related articles for article (PubMed ID: 17506513)

  • 1. Transient acid exposure increases sevelamer HCl phosphate binding.
    Ross EA; Scott WE; Odukale AA; Alba NA; Batich CD
    J Pharm Sci; 2007 Aug; 96(8):2154-60. PubMed ID: 17506513
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Relative in vitro efficacy of the phosphate binders lanthanum carbonate and sevelamer hydrochloride.
    Autissier V; Damment SJ; Henderson RA
    J Pharm Sci; 2007 Oct; 96(10):2818-27. PubMed ID: 17497733
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Gastric pH, sevelamer hydrochloride and omeprazole.
    Capitanini A; Lupi A; Osteri F; Petrone I; Del Corso C; Straniti M; Gallieni M; Rossi A
    Clin Nephrol; 2005 Oct; 64(4):320-2. PubMed ID: 16240906
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effect of gastric acid suppression with pantoprazole on the efficacy of sevelamer hydrochloride as a phosphate binder in haemodialysis patients: a pilot study.
    Lai B; Cervelli MJ
    Nephrology (Carlton); 2012 May; 17(4):402-6. PubMed ID: 22329674
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Novel dosage forms and regimens for sevelamer-based phosphate binders.
    Duggal A; Hanus M; Zhorov E; Dagher R; Plone MA; Goldberg J; Burke SK
    J Ren Nutr; 2006 Jul; 16(3):248-52. PubMed ID: 16825030
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Determination of the binding parameter constants of Renagel capsules and tablets at pH 7 by high performance capillary electrophoresis.
    Swearingen RA; Zhorov E; Cohen A; Sybertz T; Barry EF
    J Pharm Biomed Anal; 2004 Jun; 35(4):753-60. PubMed ID: 15193719
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The influence of poly(allylamine hydrochloride) hydrogel crosslinking density on its thermal and phosphate binding properties.
    Elsiddig R; O'Reilly NJ; Hudson SP; Owens E; Hughes H; O'Grady D; McLoughlin P
    Int J Pharm; 2022 Jun; 621():121806. PubMed ID: 35526696
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Kinetic and thermodynamic evaluation of phosphate ions binding onto sevelamer hydrochloride.
    Elsiddig R; Hughes H; Owens E; O' Reilly NJ; O'Grady D; McLoughlin P
    Int J Pharm; 2014 Oct; 474(1-2):25-32. PubMed ID: 25102115
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A phosphate binding assay for sevelamer hydrochloride by ion chromatography.
    Mazzeo JR; Peters RM; Hanus MR; Chen X; Norton KA
    J Pharm Biomed Anal; 1999 May; 19(6):911-5. PubMed ID: 10698557
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of fatty acids on the phosphate binding of TRK-390, a novel, highly selective phosphate-binding polymer.
    Nakaki J; Yamaguchi S; Torii Y; Inoue A; Minakami S; Kanno T; Murakami M; Tsuzuki M; Mochizuki H; Suyama K; Miyamoto M
    Eur J Pharmacol; 2013 Aug; 714(1-3):312-7. PubMed ID: 23911881
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Determination of the binding parameter constants of Renagel capsules and tablets utilizing the Langmuir approximation at various pH by ion chromatography.
    Swearingen RA; Chen X; Petersen JS; Riley KS; Wang D; Zhorov E
    J Pharm Biomed Anal; 2002 Jun; 29(1-2):195-201. PubMed ID: 12062678
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Does concomitant administration of sevelamer and calcium carbonate modify the control of phosphatemia?
    Ouellet G; Cardinal H; Mailhot M; Ste-Marie LG; Roy L
    Ther Apher Dial; 2010 Apr; 14(2):172-7. PubMed ID: 20438539
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Treatment of hyperphosphatemia with sevelamer in patients with chronic renal failure].
    Suñer M; Guerrero A; Montes R; Rivera M; Ruiz A; Martínez-García M; Pérez-Valdivia MA; Mateos J
    Nefrologia; 2004; 24(2):142-8. PubMed ID: 15219089
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Sevelamer crystals in the gastrointestinal tract (GIT): a new entity associated with mucosal injury.
    Swanson BJ; Limketkai BN; Liu TC; Montgomery E; Nazari K; Park JY; Santangelo WC; Torbenson MS; Voltaggio L; Yearsley MM; Arnold CA
    Am J Surg Pathol; 2013 Nov; 37(11):1686-93. PubMed ID: 24061514
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Molecular modeling studies of the binding characteristics of phosphates to sevelamer hydrochloride--assessing a novel technique to reduce phosphates contamination.
    Parker R; Odukale AA; Fisher D; Batich C; Ross E; Edwards J
    Int J Environ Res Public Health; 2006 Jun; 3(2):202-8. PubMed ID: 16823094
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparison of efficacy of the phosphate binders nicotinic acid and sevelamer hydrochloride in hemodialysis patients.
    Ahmadi F; Shamekhi F; Lessan-Pezeshki M; Khatami MR
    Saudi J Kidney Dis Transpl; 2012 Sep; 23(5):934-8. PubMed ID: 22982903
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effects of sevelamer and calcium-based phosphate binders on uric acid concentrations in patients undergoing hemodialysis: a randomized clinical trial.
    Garg JP; Chasan-Taber S; Blair A; Plone M; Bommer J; Raggi P; Chertow GM
    Arthritis Rheum; 2005 Jan; 52(1):290-5. PubMed ID: 15641045
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A randomized, parallel, open-label study to compare once-daily sevelamer carbonate powder dosing with thrice-daily sevelamer hydrochloride tablet dosing in CKD patients on hemodialysis.
    Fishbane S; Delmez J; Suki WN; Hariachar SK; Heaton J; Chasan-Taber S; Plone MA; Moe S
    Am J Kidney Dis; 2010 Feb; 55(2):307-15. PubMed ID: 20042256
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Sevelamer hydrochloride binds phosphate released from phytate in chicks fed 1α-hydroxy cholecalciferol.
    Bobeck EA; Meyer KM; Helvig C; Petkovich M; Cook ME
    J Ren Nutr; 2013 Jan; 23(1):21-7. PubMed ID: 22406121
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Assessment of phosphate binding by sevelamer carbonate powder for oral suspension mixed in foods.
    Hanus M; Zhorov E; Brommage D; Plone M; Holmes-Farley SR
    Nephrol Nurs J; 2012; 39(3):239-43, 255. PubMed ID: 22866363
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.